TWST - NASDAQ
Twist Bioscience Corporation
$72.33
+0.41%Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotTwist Bioscience Corporation Management Team
Ms. Angela Bitting
Chief Corporate Responsibility Officer & Senior Vice President of Corporate Affairs
Mr. Adam Laponis
Chief Financial Officer
Compensation
$810,644
Dr. Michael Fero Ph.D.
Chief Information Officer
Mr. Siyuan Chen
Chief Technology Officer
Dr. Emily Marine Leproust Ph.D.
Co-Founder, Board Chair & Chief Executive Officer
Compensation
$1,770,662
Dr. Patrick John Finn Ph.D.
President & Chief Operating Officer
Compensation
$1,092,394
Ms. Paula Green
Senior Vice President of Human Resources
Compensation
$776,221
Ms. Nicole Moreno
Senior Vice President of Sales & Support
Mr. Dennis Cho J.D.
Senior Vice President, Chief Legal Officer & Corporate Secretary
Compensation
$776,519
Mr. Robert F. Werner
Vice President & Chief Accounting Officer
Twist Bioscience Corporation Insider Positioning
During the last 12 months, insiders have sold $22.43M worth of TWST shares, with no buying activity reported.
3 Months
0
0.00
152.6K
9.16M
-9.2M
-$9.16M
3-6 Months
0
0.00
155.0K
7.31M
-7.3M
-$7.31M
6-9 Months
0
0.00
184.9K
5.76M
-5.8M
-$5.76M
9-12 Months
0
0.00
7.7K
201.52K
-202K
-$202K
Top Buyers
No buying activity
Top Sellers
Leproust Emily M.
Director, Officer: Chief Executive Officer
$7.81M
Finn Patrick John
Officer: President And Coo
$4.83M
Green Paula
Officer: Svp Of Human Resources
$3.05M
Laponis Adam
Officer: Chief Financial Officer
$2.17M
Cho Dennis
Officer: See Remarks
$2.01M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $22.43M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
TWST - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | January 06, 2026 | February 05, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | January 06, 2025 | January 06, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | January 05, 2024 | February 06, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | January 06, 2023 | February 07, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | January 04, 2022 | February 08, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | January 07, 2021 | February 03, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | January 08, 2020 | February 04, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | June 14, 2019 | July 23, 2019 | 2019 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.